Purification of clinical-grade recombinant HSP65-MUCI fusion protein

• Published in: Biotechnology and applied biochemistry Vol. 57; no. 1; p. 9
• Main Authors: Cao, Zhao, Feng, Yu, Wei, Hongfei, Fang, Mingli, Hu, Xiaoping, Yu, Yongli, Wang, Liying, Wan, Min
• Format: Journal Article
• Language: English
• Published: United States 01.09.2010
• Subjects: Antigens, Bacterial - chemistry; Antigens, Bacterial - genetics; Antigens, Bacterial - isolation & purification; Antigens, Bacterial - metabolism; Bacterial Proteins - chemistry; Bacterial Proteins - genetics; Bacterial Proteins - isolation & purification; Bacterial Proteins - metabolism; Cancer Vaccines - chemistry; Cancer Vaccines - genetics; Cancer Vaccines - isolation & purification; Cancer Vaccines - metabolism; Chaperonin 60 - chemistry; Chaperonin 60 - genetics; Chaperonin 60 - isolation & purification; Chaperonin 60 - metabolism; Chromatography, Affinity; Chromatography, Ion Exchange; Humans; Hydrogen-Ion Concentration; Minisatellite Repeats - genetics; Mucin-1 - chemistry; Mucin-1 - genetics; Mucin-1 - isolation & purification; Mucin-1 - metabolism; Mycobacterium bovis; Recombinant Fusion Proteins - chemistry; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - isolation & purification; Recombinant Fusion Proteins - metabolism

HSP65-MUCI is a fusion protein between BCG (Bacille Calmette-Guerin)-derived HSP65 (heat-shock protein 65) and human MUCI (mucin I) VNTR (variable number of tandem repeats)-domain peptides that has shown antitumour efficacy. China's Food and Drug Administration has recently approved a Phase I c...